Market Valuation & Earnings Multiples
Market capitalization, P/E ratios, and enterprise value
Market Cap872.61M
Enterprise Value849.53M
Trailing P/E5.43
ABUS
(NASDAQ)Arbutus Biopharma Corporation
$4.47-- (--)
Loading... - Market loading
Arbutus Biopharma (ABUS) Key Statistics & Financial Metrics
Complete stock analysis with 40+ metrics: valuation ratios, profitability margins, financial health indicators, and dividend data.
Stock Valuation Metrics
Market value, earnings multiples, and pricing ratios
Price-Based Ratios
Valuation ratios based on stock price
Price/Sales (ttm)4.56
Forward Price/Sales1.52
Price/Book (mrq)3.35
Price/Tangible Book (mrq)3.35
Enterprise Value Ratios
EV-based valuation multiples
EV/Revenue4.44
EV/Earnings5.29
EV/EBITDA5.32
EV/EBIT-25.43
EV/FCF-20.00
Stock Price
Current price, 52-week range, and moving averages
Current Price$4.47
1-Day Change3.23%
52-Week High$5.38
52-Week Low$3.20
52-Week Change38.39%
YTD Change-6.29%
1-Year Change37.96%
50-Day MA$4.51
200-Day MA$4.45
Avg Volume (30 day)2.66M
Share Statistics
Outstanding shares, float, and per-share metrics
Shares Outstanding195.21M
Book Value per Share$1.33
Net Cash per Share$0.12
FCF per Share$-0.22
Profitability & Financial Performance
Profit margins, return metrics, and earnings analysis
Profit Margins
Profitability margins across income statement
Gross Margin99.98%
EBITDA Margin (ttm)83.46%
EBIT Margin (ttm)-17.45%
Operating Margin (ttm)80.79%
Pretax Margin (ttm)83.95%
Profit Margin (ttm)83.95%
FCF Margin (ttm)-22.18%
Return on Investment Metrics
ROE, ROA, ROIC, and capital efficiency ratios
Return on Equity (ttm)61.77%
Return on Assets (ttm)57.99%
Return on Invested Capital (ttm)-14.09%
Return on Capital Employed (ttm)-12.28%
Income Statement (TTM)
Trailing twelve months revenue and earnings
Revenue191.44M
Gross Profit191.41M
Operating Income154.67M
Pretax Income160.72M
Net Income160.72M
EBITDA159.79M
EBIT-33.40M
Diluted EPS$0.83
Cash Flow (TTM)
Operating cash flow and free cash flow metrics
Operating Cash Flow-34.36M
Capital Expenditures8.11M
Free Cash Flow-42.47M
Growth Rates (YoY)
Year-over-year growth metrics
Revenue Growth2889.93%
Financial Health & Dividends
Balance sheet analysis, debt ratios, and dividend metrics
Assets & Cash
Total assets and cash positions
Total Assets (mrq)277.16M
Cash & Securities (mrq)23.71M
Net Cash (mrq)23.07M
Net Cash per Share$0.12
Debt & Liabilities
Liabilities, debt, equity, and working capital
Total Debt (mrq)631.00K
Working Capital (mrq)271.91M
Total Equity (mrq)260.18M
Book Value per Share$1.33
Liquidity & Leverage
Liquidity, leverage, and debt coverage ratios
Current Ratio (mrq)54.26
Quick Ratio (mrq)54.26
Debt/Equity (mrq)0.00
Debt/EBITDA (ttm)0.00
Dividend History & Payout Analysis
Dividend yield, payout ratios, and growth metrics
Dividend per Share (TTM)$0.00
Dividend Yield0.00%
Payout Ratio (Earnings)0.00%
Yield Metrics
Earnings, FCF, buyback, and shareholder yields
Earnings Yield18.42%
FCF Yield-4.87%
Buyback Yield-1.66%
Total Shareholder Yield-1.66%
Financial Health Scores
Risk assessment and quality metrics
Altman Z-Score7.47
Piotroski F-Score4/9
Fair Value & Intrinsic Value
Lynch fair value, Graham number, and valuation models
Graham Number$5.00
Graham Upside/Downside11.87%
Frequently Asked Questions About Arbutus Biopharma Statistics
What are the key financial metrics for ABUS?
Arbutus Biopharma Corporation (ABUS) statistics include 40+ financial metrics organized into valuation ratios (P/E, P/S, P/B, PEG), profitability margins (gross, operating, net), return metrics (ROE, ROA, ROIC), and financial health indicators. These are updated regularly based on the latest filings and market data.
What is ABUS's valuation analysis?
The valuation section covers market capitalization, earnings multiples like trailing and forward P/E, price-based ratios (P/S, P/B, Price/FCF), and enterprise value ratios (EV/EBITDA, EV/Revenue, EV/FCF). Compare these against sector averages to assess whether Arbutus Biopharma is overvalued or undervalued.
How do I read ABUS's profitability ratios?
Arbutus Biopharma's profitability is measured through profit margins (gross, EBITDA, operating, net) and return metrics (ROE, ROA, ROIC, ROCE). Higher margins indicate better cost control, while higher returns show efficient capital deployment. The income statement and cash flow sections provide the underlying revenue and earnings data.
What do ABUS's debt ratios indicate?
The financial health section shows Arbutus Biopharma's leverage through debt-to-equity, debt-to-assets, debt-to-EBITDA, and debt-to-FCF ratios, plus liquidity via the current and quick ratios. Lower debt ratios and higher liquidity ratios generally indicate stronger financial stability and lower default risk.
What is ABUS's dividend analysis?
The dividend section covers Arbutus Biopharma's dividend yield, payout ratios (earnings-based and FCF-based), year-over-year dividend growth, years of consecutive growth, ex-dividend and pay dates, and payment frequency. The yield metrics section also includes earnings yield, FCF yield, buyback yield, and total shareholder yield.